Some limitations in pegloticase therapy include 2-h infusion duration, twice-monthly infusions, high cost, relatively frequent infusion reactions including anaphylaxis, incompatibility in patients with glucose-6-phosphate dehydrogenase deficiency, development of antidrug antibodies (ADA), and loss of urate-lowering efficacy (Lyseng-Williamson, 2011). The gene discussed is ADA; the disease is anaphylaxis.